Loading news...
Fisher Asset Management LLC lifted its stake in shares of Cytokinetics, Incorporated (NASDAQ: CYTK) by 3.8% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 761,587 shares of the biopharmaceutical company's stock after acquiring an additional 27,907 shares during the
SOUTH SAN FRANCISCO, Calif., March 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that members of the Company management team will participate in the following investor conferences in March: Leerink 2026 Global Healthcare Conference: Fireside chat on Monday, March 9, 2026 at 9:20 AM Eastern Time in Miami Beach, FL.
CYTK reports a wider-than-expected Q4 loss as expenses rise, but Myqorzo wins FDA nod and global expansion advances, with $1.22B cash fueling 2026 catalysts.
Cytokinetics, Incorporated (CYTK) Q4 2025 Earnings Call Transcript
Cytokinetics (CYTK) came out with a quarterly loss of $1.5 per share versus the Zacks Consensus Estimate of a loss of $1.48. This compares to a loss of $1.26 per share a year ago.
MYQORZO® Approved for Adults with Symptomatic Obstructive HCM in U.S., China and Europe; U.S. Launch Underway with First Prescriptions Dispensed within Days of Drug Availability Supplemental NDA for MAPLE-HCM Submitted to FDA in Q1 2026 Expect to Share Topline Results from ACACIA-HCM in Q2 2026 Company Provides 2026 Financial Guidance; ~$1.2 Billion in Cash, Cash Equivalents and Investments as of December 31, 2025 SOUTH SAN FRANCISCO, Calif., Feb. 24, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) reported a management update and financial results for the fourth quarter and full year of 2025.
CYTK secures EU approval for Myqorzo in symptomatic obstructive HCM, expanding its first commercial drug across major global markets.
Cytokinetics (CYTK) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
European Commission Approval Based on Results of SEQUOIA-HCM First European Launch Expected in Germany in Q2 2026 SOUTH SAN FRANCISCO, Calif., Feb. 17, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that the European Commission (EC) has approved MYQORZO® (aficamten), 5 mg, 10 mg, 15 mg and 20 mg tablets for the treatment of symptomatic (New York Heart Association, NYHA, class II-III) obstructive hypertrophic cardiomyopathy (oHCM) in adult patients.
SOUTH SAN FRANCISCO, Calif., Feb. 12, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that it is scheduled to report fourth quarter results on February 24, 2026 at 4:00 PM Eastern Time.
Grants Awarded to Two Patient Advocacy Organizations to Support Communications and Community Outreach SOUTH SAN FRANCISCO, Calif., Feb. 09, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced the recipients of its eighth annual Communications Grant Program, intended to support increased communications, awareness building and community engagement.
New York State Common Retirement Fund grew its stake in Cytokinetics, Incorporated (NASDAQ: CYTK) by 24.1% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 47,875 shares of the biopharmaceutical company's stock after purchasing an additional 9,308 shares during the
Shares of Cytokinetics, Incorporated (NASDAQ: CYTK - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the twenty-one research firms that are presently covering the company, Marketbeat Ratings reports. One investment analyst has rated the stock with a sell recommendation, three have assigned a hold recommendation and seventeen have issued a buy
MYQORZO, a Cardiac Myosin Inhibitor, Directly Addresses Underlying Hypercontractility Associated with Obstructive HCM SOUTH SAN FRANCISCO, Calif., Jan. 27, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that MYQORZO™ (aficamten) is now available for prescription in 5 mg, 10 mg, 15 mg and 20 mg tablets in the U.S. MYQORZO was recently approved by the U.S. Food and Drug Administration (FDA) for the treatment of adults with symptomatic obstructive hypertrophic cardiomyopathy (oHCM) to improve functional capacity and symptoms.
LOS ANGELES--(BUSINESS WIRE)--The Law Offices of Frank R. Cruz is investigating potential claims against the board of directors of Cytokinetics, Incorporated (“Cytokinetics” or the “Company”) (NASDAQ: CYTK) concerning whether the board breached its fiduciary duties to shareholders. If you are a shareholder, click HERE to participate. On May 1, 2025, Cytokinetics disclosed that the FDA has extended the review period for its cardiac myosin inhibitor drug, aficamten, by three months, citing additi.
SOUTH SAN FRANCISCO, Calif., Jan. 20, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that on January 15, 2026 it granted stock options to purchase an aggregate of 29,416 shares of common stock and 19,825 restricted stock units (RSUs) that will be settled in shares of common stock upon vesting to 8 employees, whose employment commenced in December 2025 and January 2026 as a material inducement to their employment.
Cytokinetics, Incorporated (CYTK) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
SOUTH SAN FRANCISCO, Calif., Jan. 05, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Incorporated (Nasdaq: CYTK) today announced that Robert I.
Ethic Inc. acquired a new position in Cytokinetics, Incorporated (NASDAQ: CYTK) in the undefined quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 9,522 shares of the biopharmaceutical company's stock, valued at approximately $523,000. Other large investors have also bought and sold shares
PHILADELPHIA, Jan. 02, 2026 (GLOBE NEWSWIRE) -- Cytokinetics, Inc. (NASDAQ: CYTK): Grabar Law Office is investigating claims on behalf of shareholders of Cytokinetics, Inc. (NASDAQ: CYTK). The investigation concerns whether certain officers and directors breached the fiduciary duties they owed to the company.